Tag: Immunotherapeutics
Abnormal volumes on the Paris stock exchange: Ose Immunotherapeutics, Atos
During this stock market session on Friday April 19, 2024, particularly high trading volumes were detected on the French market. Today, it is the Ose Immunotherapeutics stock that stands out,…
Abnormal volumes on today’s session: Medincell, Ose Immunotherapeutics
During this stock market session on Wednesday April 17, 2024, particularly high trading volumes were detected on the French market. Today, it is Medincell stock that stands out, with trading…
Ose Immunotherapeutics: entry into force of the license for Ose 230 – 04/17/2024 at 10:31
(AOF) – Ose Immunotherapeutics announces the entry into force of the global license to develop an innovative monoclonal antibody in the treatment of chronic inflammation. The biotech announces the end…
OSE Immunotherapeutics receives €8.4 million in public funding to support the Phase 3 clinical trial for the registration of the Tedopi® vaccine against lung cancer – 04/10/2024 at 6:00 p.m.
Nantes, France, April 10, 2024, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces that the Company has received non-dilutive financing of 8.4 million euros as part…
OSE Immunotherapeutics accentuates its losses in 2023
(AOF) – OSE Immunotherapeutics announces a cash position of 18.7 million euros as of December 31, 2023, to which will be added $48 million expected under the agreement with AbbVie…
OSE Immunotherapeutics announces the end of recruitment in the Phase 2 clinical study of Lusvertikimab evaluated in patients suffering from ulcerative colitis – 03/18/2024 at 07:30
Nantes, France – March 18, 2024, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announces the end of recruitment in the Phase 2b clinical trial evaluating the…
OSE Immunotherapeutics: partnership with AbbVie for OSE-230
By Arnaud Bivès Published on 02/28/2024 at 7:57 a.m. (Boursier.com) — OSE Immunotherapeutics and AbbVie announce a…
Unusual volumes on the stock market today: Ose Immunotherapeutics, Teleperformance
During this stock market session on Wednesday February 28, 2024, particularly high trading volumes were detected on the French market. Today, it is the Ose Immunotherapeutics stock that stands out,…
Ose Immunotherapeutics jumps after its partnership with Abbvie
(AOF) – Ose Immunotherapeutics (+54.61% to 5.11 euros) posts the strongest increase in the SRD market after announcing a global collaboration and licensing agreement with the American Abbvie to develop…
OSE Immunotherapeutics: new positive results against advanced solid tumors
(AOF) – OSE Immunotherapeutics presents the latest positive results from the Phase 1/2 clinical evaluation of its product OSE-279 in advanced solid tumors at the 2024 ESMO Targeted Anticancer Therapies…
OSE Immunotherapeutics and the Nantes University Hospital Center present a positive interim analysis of the Phase 1/2 FIRsT clinical trial evaluating FR104/VEL-101 immunotherapy in kidney transplantation – 11/12/2023 at 07:30
At the annual congress of the Société Francophone de Transplantation Supported by the European Society of Organ Transplantation (ESOT) Nantes, France – December 11, 2023, 7:30 a.m. – OSE Immunotherapeutics…
OSE Immunotherapeutics announces a collaboration agreement with GenDx for the development of a companion diagnostic test associated with Tedopi®, its epitope-based cancer vaccine candidate – 11/21/2023 at 6:00 p.m.
• A development program to support the next pivotal confirmatory phase 3 clinical trial currently being prepared.• A companion diagnostic test to identify HLA-A*02 positive cancer patients eligible for treatment…